~ Diulcus, developed by NovaLead Pharma, shows promising results in clinical trials with a 77.20% ulcer closure rate ~
~Approved by CDSCO and partially funded by BIRAC
According to the ICMR-INDIAB (2023) study, 100 million people in India are living with diabetes, while another 136 million are in the pre-diabetes stage. This alarming trend places India on the path to becoming the diabetes capital of the world by 2030.
In response to this critical health challenge, IPCA Laboratories Ltd is proud to introduce Diulcus, a groundbreaking product designed to address the complexities of Diabetic Foot Ulcer (DFU) in the Indian market. Developed by NovaLead Pharma Pvt Ltd, a leader in drug repurposing, Diulcus marks a significant leap forward in DFU management. The product has been approved by the Central Drugs Standard Control Organization (CDSCO) and was partly funded by the Biotechnology Industry Research Assistance Council (BIRAC), a Government of India enterprise.
The launch event was graced by esteemed personalities, including Sri. Premchand Godha, Sri AK Jain, Dr. Anil Pareek, Sri Sunil Ghai, and Sri. Supreet Deshpande.
During phase 3 trials in India, Diulcus demonstrated remarkable efficacy, with a 60.3% ulcer closure rate within three months of treatment. Remarkably, patients continued to show an ulcer closure rate of 77.20% over six months, even after stopping treatment at three months. These results are among the best observed for any pharmaceutical preparation used in DFU treatment.
Mr. Premchand Godha, Executive Chairman of IPCA Laboratories Ltd, expressed his enthusiasm about the launch, stating, “With over 15% of diabetic patients suffering from DFU at least once in their lifetime, DFU is the most prevalent complication caused by chronic diabetes. The approval of this patented repurposed drug is significant because DFU is the leading cause for lower limb amputations globally. We are delighted to partner with NovaLead Pharma Pvt Ltd through an IP licensing arrangement to bring Diulcus® for DFU patients in India. It demonstrates IPCA’s commitment towards the patients suffering from unmet medical need and its focus on the diabetes therapy.”
Diulcus will be made available to the patients of DFU by Ipca Laboratories Ltd. (Ipca) through an exclusive IP licensing arrangement with NovaLead for Indian starting August 2024.
